Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
127-31-1
Molecular formula
C21H29FO5
Molecular weight
380.4 g/mol
Drug class
Synthetic mineralocorticoidglucocorticoid receptor agonist with strong mineralocorticoid activity
Mechanism of action
Activates mineralocorticoid receptors in the distal nephron, increasing sodium reabsorption and potassium/hydrogen ion excretion, thereby expanding extracellular fluid volume and supporting blood pressure. It also has glucocorticoid activity.
Indications / reported uses
Replacement therapy for mineralocorticoid deficiency in primary adrenal insufficiency (Addison disease) and selected forms of congenital adrenal hyperplasia
Selected off-label use for orthostatic hypotension; this is not a universal product-authorised indication
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Fludrocortisone Environmental Risk Assessment (ERA) (the Fludrocortisone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.